Direxion Daily S&P Biotech Bear 3X ETF (LABD)
10.51
-0.52
(-4.71%)
USD |
NYSEARCA |
Apr 26, 16:00
10.46
-0.05
(-0.48%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 1.10% | 0.00% | 93.93M | 14.84M |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 4.21% | 0.00% | 105.20M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests at least 80% of the fund’s net assets in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 3X daily inverse (opposite) or short exposure to the index or to ETFs that track the index, consistent with the fund’s investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the GICS. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Inverse Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Biotechnology Select Industry TR USD | -300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 8.85 yrs |
| Tony Ng | 8.51 yrs |
Performance Versus Category
As of April 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 25, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests at least 80% of the fund’s net assets in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 3X daily inverse (opposite) or short exposure to the index or to ETFs that track the index, consistent with the fund’s investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the GICS. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Inverse Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Biotechnology Select Industry TR USD | -300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 8.85 yrs |
| Tony Ng | 8.51 yrs |